Headline

Top March 2012 Quarter Picks From $1 Billion Pure-Play Biotech Swiss Hedge Fund BB Biotech

Tweet Switzerland-based BB Biotech, founded in 1993, is one of the largest pure-play biotech investment companies, and also a public company with its shares are listed on the Swiss Stock Market. About a third of its assets are invested in oncology-focused biotech companies, another 20% in infectious-disease focused biotech companies, and about 15% each in metabolic and cardiovascular focused biotech companies. As of the most recent filing for the March 2012 quarter, filed with the SEC on Wednesday, it held $1.01 billion in 13-F assets, making concentrated bets in just 20 companies. Based on the net asset value (NAV), its stock has returned 23.7% YTD and 390.5% since inception in November, 1993. Two of BB Biotech’s companies got acquired during the quarter. This included Micromet, in which it owned 6.8 million … Read entire article »